Physical interaction: ondansetron + dexamethasone

The term Physical interaction: ondansetron + dexamethasone does not refer to a single molecular target but rather describes the pharmacological synergy and pharmaceutical compatibility between two distinct drugs: ondansetron and dexamethasone. Ondansetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the peripheral vagal nerve terminals and the central chemoreceptor trigger zone (StatPearls, 2023). Dexamethasone is a potent corticosteroid that acts as a glucocorticoid receptor agonist, likely reducing emesis by inhibiting prostaglandin synthesis and decreasing the permeability of the blood-brain barrier to emetogenic toxins (NIH, 2022). When used in combination, these agents provide superior protection against chemotherapy-induced nausea and vomiting (CINV) compared to either drug alone, representing a standard of care in oncology (PMID: 10713581). From a physical pharmacy perspective, this interaction also refers to the stability of the two drugs when mixed in the same intravenous bag or syringe. Studies have shown that ondansetron hydrochloride and dexamethasone sodium phosphate are generally physically compatible and chemically stable in common diluents like 0.9% Sodium Chloride for up to 48 hours at room temperature, though clinicians must monitor for precipitation if concentrations exceed specific thresholds (Trissel's Handbook on Injectable Drugs). Because this entry describes a drug-drug relationship rather than a specific protein, enzyme, or receptor, it is classified as an incorrect target designation.

Other names

Ondansetron and dexamethasone combinationOndansetron-dexamethasone synergyAntiemetic combination therapyOndansetron-dexamethasone pharmaceutical compatibility

Synergistic inhibition of emetic pathways via 5-HT3 receptor antagonism and glucocorticoid receptor-mediated anti-inflammatory effects.